BioVaxys Technology Corp. @biovaxys Nearly $130M has been spent over the years advancing Dr. Berd’s #cancer #immunotherapeutic platform. We look forward to launching the #ovariancancer #vaccine trial in the EU and moving closer towards commercialization. 4:00 PM · Oct 12, 2022 ·Twitter Web App